CA3050086A1 - Glatiramer depot systems for treating progressive forms of multiple sclerosis - Google Patents

Glatiramer depot systems for treating progressive forms of multiple sclerosis

Info

Publication number
CA3050086A1
CA3050086A1 CA3050086A CA3050086A CA3050086A1 CA 3050086 A1 CA3050086 A1 CA 3050086A1 CA 3050086 A CA3050086 A CA 3050086A CA 3050086 A CA3050086 A CA 3050086A CA 3050086 A1 CA3050086 A1 CA 3050086A1
Authority
CA
Canada
Prior art keywords
glatiramer
depot formulation
patient
certain embodiments
depot
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3050086A
Other languages
English (en)
French (fr)
Inventor
Uri DANON
Nadav BLEICH KIMELMAN
Laura POPPER
Ehud Marom
Original Assignee
Mapi Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd filed Critical Mapi Pharma Ltd
Publication of CA3050086A1 publication Critical patent/CA3050086A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3050086A 2017-03-26 2018-03-25 Glatiramer depot systems for treating progressive forms of multiple sclerosis Pending CA3050086A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762476794P 2017-03-26 2017-03-26
US62/476,794 2017-03-26
PCT/IL2018/050340 WO2018178973A1 (en) 2017-03-26 2018-03-25 Glatiramer depot systems for treating progressive forms of multiple sclerosis

Publications (1)

Publication Number Publication Date
CA3050086A1 true CA3050086A1 (en) 2018-10-04

Family

ID=63674352

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3050086A Pending CA3050086A1 (en) 2017-03-26 2018-03-25 Glatiramer depot systems for treating progressive forms of multiple sclerosis

Country Status (10)

Country Link
US (3) US11167003B2 (2)
EP (1) EP3600553B1 (2)
JP (3) JP7602322B2 (2)
CN (1) CN110382052A (2)
AU (1) AU2018242998B2 (2)
BR (1) BR112019017724A2 (2)
CA (1) CA3050086A1 (2)
IL (2) IL316573A (2)
MX (1) MX2019010174A (2)
WO (1) WO2018178973A1 (2)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49251E1 (en) * 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
MX2019001999A (es) 2016-08-28 2019-08-29 Mapi Pharma Ltd Proceso para la preparacion de microparticulas que contienen acetato de glatiramer.
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
CN110382052A (zh) * 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
WO2021173740A1 (en) * 2020-02-28 2021-09-02 Genentech, Inc. Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase
WO2025150035A1 (en) * 2024-01-11 2025-07-17 Mapi Pharma Ltd. Treatment of primary progressive multiple sclerosis

Family Cites Families (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
ES2017924B3 (es) 1985-10-11 1991-03-16 Duphar Int Res B V Inyector automatico.
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
HU221294B1 (en) 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5578442A (en) 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5643605A (en) 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5858964A (en) 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
IT1276690B1 (it) 1995-06-09 1997-11-03 Ira Srl Sistema di inclusione a rilascio controllato di acido glicolico in beta-ciclodestrine e procedimento di preparazione di detto sistema
WO1997026869A1 (en) 1996-01-24 1997-07-31 United States Government Represented By The Secretary Of The Army Novel 'burst-free' sustained release poly-(lactide/glycolide) microspheres
MX336813B (es) 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US20070185032A1 (en) 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
IL119989A0 (en) 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
MY118835A (en) 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
US6454746B1 (en) 1997-06-04 2002-09-24 Eli Lilly And Company Medication delivery apparatus
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
EP1054880A1 (en) 1998-02-13 2000-11-29 Autoimmune, Inc. TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
WO2000005249A2 (en) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
DK2239269T3 (da) 1998-09-25 2013-04-29 Yeda Res & Dev Anvendelse af peptider afledt af copolymer-1 som molekylvægtsmarkører
WO2000020010A1 (en) 1998-10-02 2000-04-13 Yeda Research And Development Co., Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
AU775073C (en) 1998-11-12 2007-05-03 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6872739B1 (en) 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
US6531130B1 (en) 1999-07-06 2003-03-11 The Board Of Trustees Of The Leland Stanford University Treatment of demyelinating autoimmune disease with ordered peptides
JP4328050B2 (ja) 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
IL150895A0 (en) 2000-02-18 2003-02-12 Teva Pharma Oral, nasal and pulmonary formulations of copolymer-1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
HUP0302333A3 (en) 2000-06-05 2005-07-28 Teva Pharma The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
EP1294390B1 (en) 2000-06-07 2006-01-04 YEDA RESEARCH AND DEVELOPMENT CO., Ltd. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotection from glutamate toxicity
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
KR100392501B1 (ko) 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
WO2008150547A1 (en) 2007-06-04 2008-12-11 The Regents Of The University Of California Pregnancy hormone combination for treatment of autoimmune diseases
US6835711B2 (en) 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy
JP4426286B2 (ja) 2001-07-10 2010-03-03 テバ ファーマシューティカル インダストリーズ リミティド ０次、０次−二相性、上昇型又は下降型薬物放出のための薬物送達システム
DE02800437T1 (de) 2001-10-03 2004-11-11 The President And Fellows Of Harvard College, Cambridge Copolymere zur unterdrückung von autoimmunkrankheiten und anwendungsverfahren
US7132438B2 (en) 2001-10-09 2006-11-07 Amgen Inc. Benzimidazole derivatives
WO2003048207A2 (en) 2001-11-28 2003-06-12 Immunomedics, Inc. Anti-dota antibody
US7429374B2 (en) 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
US7351686B2 (en) 2001-12-06 2008-04-01 Yeda Research And Development Co. Ltd. Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
CN1398584A (zh) 2002-07-15 2003-02-26 裴福兴 一种bFGF－PLGA缓释微球及其制备方法和用途
DE10237146A1 (de) 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
WO2004041285A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
WO2004043995A2 (en) 2002-11-13 2004-05-27 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
AU2003275895B2 (en) 2002-11-25 2009-02-05 Tecpharma Licensing Ag Auto-injector comprising a resettable releasing safety device
ES2386435T3 (es) 2003-01-07 2012-08-21 Yeda Research And Development Co., Ltd. Vacuna en forma de gotas oculares que contiene copolímero 1 para inmunización terapéutica
RU2339397C2 (ru) 2003-01-21 2008-11-27 Йеда Рисерч Энд Дивелопмент Ко.Лтд. Сор1 для лечения воспалительных заболеваний кишечника
US20070037740A1 (en) 2003-03-04 2007-02-15 Irit Pinchasi Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
WO2004103297A2 (en) 2003-05-14 2004-12-02 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
BRPI0412735A (pt) 2003-07-18 2006-09-26 Baxter Int métodos para a fabricação, uso e composição de partìculas esféricas pequenas preparadas mediante a separação de fase controlada
US20050142205A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US20060276390A1 (en) 2003-07-31 2006-12-07 Yeda Research And Development Co. Ltd. Combined treatments comprising synthetic peptide copolymers for preventing graft rejection
JP2007509981A (ja) 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子
JP5456235B2 (ja) 2003-11-12 2014-03-26 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経変性疾患を治療するためのワクチン及び方法
CA2553254C (en) 2004-01-12 2013-12-17 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
AU2005219876A1 (en) 2004-03-01 2005-09-15 Peptimmune, Inc. Methods and compositions for treatment of autoimmune diseases
EP1778286A4 (en) 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
US7576051B2 (en) 2004-03-11 2009-08-18 Sanyo Chemical Industries, Ltd. Wound dressing for accelerating epidermal regeneration
AU2005226729B2 (en) 2004-03-25 2010-01-28 Janssen Pharmaceutica N.V. Imidazole compounds
US20060194725A1 (en) 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
JP5495490B2 (ja) 2004-05-07 2014-05-21 アレス トレーディング エスエイ ランダム共重合体を用いる疾患の治療方法
AU2005249566B2 (en) 2004-06-04 2010-11-11 Genentech, Inc. Method for treating multiple sclerosis
US8053197B2 (en) 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
EP1796710A4 (en) 2004-09-02 2010-05-26 Teva Pharma THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS
HRP20160455T1 (hr) 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
ZA200702591B (en) 2004-09-09 2009-03-25 Teva Pharma Process for preparation of mixtures of polypeptides using purified hydrobromic acid
AR052321A1 (es) 2004-10-29 2007-03-14 Sandoz Ag Procesos para la preparacion de un polipeptido
CA2587597A1 (en) 2004-11-19 2006-05-26 Biogen Idec Ma Inc. Treatment for multiple sclerosis
ES2541780T3 (es) 2004-11-29 2015-07-24 Yeda Research And Development Co., Ltd. Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1
JP2008528589A (ja) 2005-02-02 2008-07-31 テバ ファーマシューティカル インダストリーズ リミティド 水素化分解を用いてポリペプチド混合物を作成する方法
AU2006211101A1 (en) 2005-02-02 2006-08-10 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Synthetic peptide copolymers for treatment and prevention of cardiovascular disorders
US20080279819A1 (en) 2005-02-15 2008-11-13 Adamas Pharmaceuticals, Inc. Combinations Therapy for Treatment of Demyelinating Conditions
WO2006089164A1 (en) 2005-02-17 2006-08-24 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
US20100167983A1 (en) 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2606194A1 (en) 2005-04-25 2006-11-02 Yeda Research And Development Company Markers associated with the therapeutic efficacy of glatiramer acetate
EP2354140A1 (en) 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2007021970A2 (en) 2005-08-15 2007-02-22 Praecis Pharmaceuticals, Inc. Stable pharmaceutical formulations and methods of use thereof
US20070059798A1 (en) 2005-09-09 2007-03-15 Alexander Gad Polypeptides useful for molecular weight determinations
US7517856B2 (en) 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
WO2007081975A2 (en) 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20070207141A1 (en) 2006-02-28 2007-09-06 Ivan Lieberburg Methods of treating inflammatory and autoimmune diseases with natalizumab
US8410115B2 (en) 2006-02-28 2013-04-02 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
HUE035980T2 (hu) 2006-03-15 2018-06-28 Brigham & Womens Hospital Inc Gelzolin alkalmazása szklerózis multiplex kezelésére és neurológiai betegségek diagnosztizálására
ES2565035T3 (es) 2006-04-28 2016-03-30 Momenta Pharmaceuticals, Inc. Métodos para evaluar mezclas de péptidos
US20080118553A1 (en) 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
AU2007264682B2 (en) 2006-06-28 2012-09-06 Yeda Research & Development Co. Ltd Method of treatment of age-related macular degeneration
MX2008016335A (es) 2006-06-30 2009-01-21 Abbott Biotech Ltd Dispositivo automatico de inyeccion.
JP2009542864A (ja) 2006-07-05 2009-12-03 モメンタ ファーマシューティカルズ インコーポレイテッド コポリマー１の調製のための改良法
WO2008060786A2 (en) 2006-10-06 2008-05-22 Baxter International Inc. Microencapsules containing surface-modified microparticles and methods of forming and using the same
EP2109364A4 (en) 2006-12-15 2010-04-14 Abbott Lab NOVEL OXADIAZONE COMPOUNDS
WO2008075365A1 (en) 2006-12-20 2008-06-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for treatment of age related degeneration of the retina
ES2599227T3 (es) 2007-02-08 2017-01-31 Biogen Ma Inc. Neuroprotección en enfermedades desmielinizantes
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US8138201B2 (en) 2007-07-11 2012-03-20 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
WO2009040814A1 (en) 2007-09-24 2009-04-02 Hadasit Medical Research Services & Development Ltd Use of copolymer 1 for treatment of muscular dystrophy
WO2009042193A1 (en) 2007-09-25 2009-04-02 Abbott Laboratories Octahydropentalene compounds as chemokine receptor antagonists
US8394763B2 (en) 2007-09-26 2013-03-12 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009063459A2 (en) 2007-11-13 2009-05-22 Yeda Research And Development Co. Ltd Synthetic peptide copolymers for treatment of neurodevelopmental disorders
CA2702437C (en) 2007-11-28 2013-06-25 Teva Pharmaceutical Industries Ltd. Method of delaying the onset of clinically definite multiple sclerosis
ES2329327B1 (es) 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
JP2011529078A (ja) 2008-07-25 2011-12-01 ザ・ジョンズ・ホプキンス・ユニバーシティー 自己免疫疾患を治療および予防するための方法および組成物
WO2010024908A1 (en) 2008-08-26 2010-03-04 Fibrogen, Inc. Methods for treatment of multiple sclerosis
AU2009291781A1 (en) 2008-09-10 2010-03-18 Acorda Therapeutics, Inc. Methods of using sustained release aminopyridine compositions
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010045265A1 (en) * 2008-10-13 2010-04-22 Biovista, Inc. Compositions and methods for treating multiple sclerosis
DE102008058917A1 (de) 2008-11-25 2010-05-27 Volkswagen Ag Verfahren und Vorrichtung zum Fügen von Werkstücken
US20110268699A1 (en) 2008-12-11 2011-11-03 Biovista, Inc. Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
CN102804165A (zh) 2009-02-11 2012-11-28 四次方有限公司 具有可扩展数据路径的前端处理器
WO2010096558A1 (en) 2009-02-18 2010-08-26 Eyeon Particle Sciences Llc Bi-functional co-polymer use for ophthalmic and other topical and local applications
JP5308510B2 (ja) 2009-02-26 2013-10-09 パナソニック株式会社 位相調整回路
EP2246048A1 (en) 2009-04-30 2010-11-03 Santhera Pharmaceuticals (Schweiz) AG Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis
NZ577731A (en) 2009-06-16 2010-08-27 Innate Therapeutics Ltd Compositions and methods for treatment of multiple sclerosis
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
CA2697570C (en) 2009-07-15 2011-11-01 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
AU2013203367C1 (en) 2009-08-20 2018-01-18 Yeda Research & Development Co., Ltd Low frequency glatiramer acetate therapy
NZ598661A (en) * 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy
WO2011048208A1 (en) 2009-10-22 2011-04-28 University College Dublin, National University Of Ireland, Dublin Causal therapy of diseases or conditions associated with cns or pns demyelination
HUE060304T2 (hu) 2010-01-04 2023-02-28 Mapi Pharma Ltd Glatiramer acetátot tartalmazó depó rendszer
US8377885B2 (en) * 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US20130046015A1 (en) 2010-02-11 2013-02-21 Robert C. Axtell Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease
EP2982371A1 (en) 2010-02-12 2016-02-10 Biogen MA Inc. Dimethyl fumarate with glatiramer acetate or interferon-beta for treating multiple sclerosis
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US9109006B2 (en) 2010-07-29 2015-08-18 Santhanakrishnan Srinivasan Glatiramer acetate molecular weight markers
JP5655147B2 (ja) 2010-08-20 2015-01-14 セルリアン・ファーマ・インコーポレイテッド 治療用ペプチド−ポリマーの複合体、粒子、組成物および関連の方法
CA2814500A1 (en) 2010-10-11 2012-04-19 Teva Pharmaceutical Industries Ltd Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
GB2485169A (en) 2010-11-03 2012-05-09 Univ Jw Goethe Frankfurt Main (R)-flurbiprofen for use in the treatment of multiple sclerosis
EP2500072A1 (en) 2011-03-15 2012-09-19 LEK Pharmaceuticals d.d. A novel process of residual solvent removal
WO2012139058A1 (en) 2011-04-08 2012-10-11 Biogen Idec Ma Inc. BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF
NZ713461A (en) 2011-04-15 2017-02-24 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
WO2012143924A1 (en) * 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
FI3467509T3 (fi) 2011-05-04 2026-02-11 Cellular Tech Ltd Cns-antigeenispesifisiä b-solu-, t-solu- ja vasta-ainemäärityksiä ja niiden käyttötapoja multippeliskleroosin diagnosoinnissa ja hoidossa
US20140348861A1 (en) 2011-05-05 2014-11-27 National Institute Of Immunology Synthetic peptides and random copolymers for the treatment of autoimmune disorders
ES2456917T3 (es) 2011-05-31 2014-04-24 Laboratorios Farmacéuticos Rovi, S.A. Formulación de implante de paliperidona
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
MX2014010987A (es) 2012-03-12 2015-03-03 Medimmune Llc Tratamiento de esclerosis multiple con anticuerpo anti-cd19.
GB201208850D0 (en) 2012-05-18 2012-07-04 Alphaptose Gmbh Tri-subsituted glycerol compounds for use in the treatment of clinically isolated syndrome and/or multiple sclerosis
US9132138B2 (en) 2012-08-27 2015-09-15 Casi Pharmaceuticals, Inc. Method for the treatment of multiple sclerosis
CA2887682A1 (en) 2012-10-09 2014-04-17 Biogen Idec Ma Inc. Combination therapies and uses for treatment of demyelinating disorders
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
MX2015008754A (es) 2013-01-04 2016-04-11 Teva Pharma Caracterizacion de un medicamento relacionado con acetato de glatiramer.
CN109432073A (zh) 2013-01-08 2019-03-08 帕萨罗杰卡有限公司 Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途
BR112015019564A2 (pt) 2013-02-15 2017-07-18 Teva Pharma tratamento de esclerose múltipla com laquinimod
US20140271630A1 (en) 2013-03-12 2014-09-18 Teva Pharmaceutical Industries, Ltd. Rituximab induction therapy followed by glatiramer acetate therapy
US20160040236A1 (en) 2013-03-15 2016-02-11 Biogen Ma Inc. Systems and methods for characterization of multiple sclerosis
CN103169670B (zh) 2013-03-22 2016-07-06 深圳翰宇药业股份有限公司 一种醋酸格拉替雷微球及其制备方法
AU2014319921A1 (en) 2013-09-11 2016-03-17 Compugen Ltd. Anti-VSTM5 antibodies and the use thereof in therapy and diagnosis
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US10493122B2 (en) * 2014-03-17 2019-12-03 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
US10799512B2 (en) 2014-04-28 2020-10-13 The Regents Of The University Of California Estrogen combination for treatment of multiple sclerosis
EP3188735A4 (en) 2014-09-02 2018-01-24 The Regents of the University of California Estrogen therapy for brain gray matter atrophy and associated disability
EP3782616B1 (en) 2014-09-02 2023-11-01 The Regents of The University of California Estrogen receptor ligand treatment for neurodegenerative diseases
WO2016040861A1 (en) 2014-09-12 2016-03-17 Biogen Ma Inc. Systems and methods for characterization of multiple sclerosis
WO2016064997A1 (en) 2014-10-22 2016-04-28 The Regents Of The University Of California Compositions and methods for treating fatigue and depression
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
US20160213633A1 (en) 2015-01-28 2016-07-28 Teva Pharmaceutical Industries, Ltd. Method of inducing anti-glatiramer acetate antibody response
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
WO2016160830A1 (en) 2015-03-30 2016-10-06 The Regents Of The University Of California Methods of providing neuroprotective therapy
WO2016160832A1 (en) 2015-03-30 2016-10-06 The Regents Of The University Of California Methods of monitoring estriol therapy
WO2018002930A1 (en) 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
MX2019001999A (es) * 2016-08-28 2019-08-29 Mapi Pharma Ltd Proceso para la preparacion de microparticulas que contienen acetato de glatiramer.
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
EP3624815A4 (en) * 2017-05-15 2021-01-20 Stem Cell Medicine Ltd. TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS

Also Published As

Publication number Publication date
JP7802122B2 (ja) 2026-01-19
AU2018242998A1 (en) 2019-08-01
JP7602322B2 (ja) 2024-12-18
US20250352607A1 (en) 2025-11-20
MX2019010174A (es) 2019-10-15
US11167003B2 (en) 2021-11-09
IL269555A (en) 2019-11-28
BR112019017724A2 (pt) 2020-03-31
EP3600553B1 (en) 2026-05-06
EP3600553A1 (en) 2020-02-05
CN110382052A (zh) 2019-10-25
US20200376069A1 (en) 2020-12-03
IL316573A (en) 2024-12-01
JP2024153882A (ja) 2024-10-29
US20220023377A1 (en) 2022-01-27
US12343371B2 (en) 2025-07-01
WO2018178973A1 (en) 2018-10-04
JP2020515530A (ja) 2020-05-28
JP2023022174A (ja) 2023-02-14
EP3600553A4 (en) 2020-09-02
AU2018242998B2 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
US12343371B2 (en) Method for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using a sustained release depot formulation comprising glatiramer acetate
CA2784394C (en) Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
AU2017319728B2 (en) Depot systems comprising glatiramer acetate
US8377885B2 (en) Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
USRE50301E1 (en) Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
HK40010052A (en) Glatiramer depot systems for treating progressive forms of multiple sclerosis
HK40005874A (en) Depot systems comprising glatiramer acetate

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220725

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250312

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250317

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250317

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250624

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250702

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250724

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250724

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260316

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260316